Alabama legalized medical cannabis in 2021. Litigation over the licensing process delayed actual sales for five years — the state's first dispensary, Callie's Apothecary in Montgomery, opened June 3-4, 2026. A second location opened in Talladega on August 28. The program allows no flower, no smoking,
Texas ran a medical cannabis program more restrictive than comparator states for a decade: three dispensing organizations, all in central Texas, selling mostly edibles, tinctures, and beverages capped at 0.5–1% THC by weight, with no overnight product storage allowed outside the home dispensary. A 2024 state-commissioned evaluation
Georgia's medical cannabis program spent years capped at 5% THC, with no smokable or vaporizable flower allowed. On July 1, 2026, that changed — GMCC says the new products are available at both dispensaries and independent pharmacies, though how consistently that's playing out at the pharmacy counter
Kentucky doesn't publish a revenue dashboard, but the real number exists — it surfaced in legislative testimony instead. OMC told the state legislature on July 2 that Kentucky had shipped $4.4 million worth of product to dispensaries as of June 11 — a wholesale figure, corrected here to roughly
Before Delaware's adult-use launch, Marijuana Commissioner Rob Coupe projected the state's legal cannabis market would reach $281 million in its first year — extrapolating existing medical patient spending (about $3,303/year per patient) across an estimated 85,000 future customers. Actual first-year sales came
New Hampshire's therapeutic cannabis program enrolled 16,846 patients as of June 2025 — up 14.6% in a single year, its strongest growth since the 2018–2020 expansion phase — served by three nonprofit operators holding four statutory Alternative Treatment Center certificates across seven dispensing locations. RSA 126-X:
South Dakota and North Dakota are, for cannabis-policy purposes, close to a matched pair: nearly identical Republican supermajorities, nearly identical median income and education, nearly identical rejection of adult-use legalization, and populations within 17% of each other. South Dakota's medical program still enrolls roughly double North
North Dakota's medical marijuana program sold $22.4 million in fiscal year 2024 through eight dispensaries supplied by exactly two manufacturers — the maximums state law permits without a regulatory finding that has never been made. Under the framework's assumptions, the legal channel captures roughly 11% of
Iowans spend an estimated three-quarters of a billion dollars a year on cannabis. About $13.7 million of it — 1.8% — passes through the state's five licensed dispensaries. The rest, roughly $760 million annually — about $2.1 million every day — is spending Iowa's medical channel
Louisiana's medical cannabis program runs on just two licensed producers supplying a hard-capped 30 dispensaries statewide. Wholesale distribution to pharmacies reached an estimated $90.9 million in the year ending June 2025 — a figure independently confirmed two ways, once by state tax collections and once by industry
Washington DC voters approved cannabis legalization in 2014 with 70% of the vote. Eleven years later, the city still has no licensed adult-use market. What it has instead is a medical program that functions as a de facto adult-use channel for anyone willing to register, a "gifting&
Missouri's cannabis market generated $1.52 billion in 2025 — $1.34 billion adult-use, $174 million medical — against an estimated resident demand the framework puts near 280 million grams. That works out to a blended price of about $5.42 per gram and resident capture north of 90%
Washington legalized adult-use cannabis in 2012 alongside Colorado and is now the clearest case study in what a mature, oversupplied, commodity-floor market looks like. FY2025 legal sales of roughly $1.18 billion against an estimated 387.6 million grams of resident demand work out to a blended all-
Mississippi's medical cannabis program generated $138.9M in CY 2025 across 66,041 active patient cardholders, capturing an estimated 16% of modeled demand at $6.43/g flower pricing. The third-year program is growing strongly — sales up 43.8% year-over-year, with patient enrollment up 33%
Utah's medical cannabis program serves 113,202 active cardholders across 15 dispensaries — a retail footprint so constrained that statewide remote-order channels handle roughly a third of all sales. After six years of operation, the program runs at a $183M annualized pace and has generated $750M in cumulative
Alaska legalized adult-use cannabis through Ballot Measure 2 in 2014, with the first licensed sales in 2016. A decade later it captures an estimated 95% of resident demand — among the highest rates of any market — for a reason almost no other state shares: geographic isolation raises the cost of
Arizona launched adult-use cannabis sales on January 22, 2021 — 80 days after the election, the fastest implementation of a voter-approved legalization measure in U.S. history. Four years later, the state generated $1.22 billion in combined medical and adult-use sales in 2025 against a resident consumer
West Virginia has 64 operational dispensaries, 9 growers, and a medical cannabis program that generated an estimated $93 million in 2025 — all serving approximately 35,000 registered patients in one of the poorest states in the country. Prices have fallen 15.4% in two years as indoor-only producers compete
Arkansas has run a medical cannabis program since 2019 and generated $291 million in sales in 2025 — a new state record. The math behind that number is unusual: approximately 110,000 active patient cardholders, each spending roughly $210/month, are carrying the entire regulated market. The other three-quarters of
Vermont launched adult-use retail in October 2022 with a regulatory framework built around small-scale outdoor cultivators, sustainability, and deliberate market development. About nine months after launch, catastrophic flooding hit the state's predominantly outdoor cultivation base and drove prices up through mid-2024. Vermont is the only
Oklahoma passed SQ 788 in 2018 with no qualifying condition list — patients need only a recommendation from an OMMA-registered physician in good standing. The result is a medical program that functions as adult use in everything but name: $2.11/g flower, 1,398 licensed dispensaries, and the lowest
New Mexico peaked at $590 million in 2024 and is now declining. But the headline number obscures two separate stories: 61.9% flower price compression since launch, and a border export market that has grown 301% since launch and now accounts for nearly 20% of all state revenue. Market Overview
Nevada's cannabis market peaked at $965 million in FY22 and has declined 28% to a $695 million annualized pace. But the decline isn't a failure — it's what happens after you've already captured every gram of resident demand and prices keep falling. Market
New Jersey's cannabis market crossed $1 billion in 2024 and is on pace for $1.16 billion in 2025 — but volume is the story, not revenue. Adult-use flower prices have fallen 35% in 21 months while grams sold have increased 38%. Market Overview New Jersey legalized adult-